Abstract
Introduction
Although protein-based therapeutics were seen as a risky and diffi cult fi eld of endeavor, the biopharmaceutical industry's persistent pursuit of such agents created a multi-billion-dollar marketplace and a host of life-saving treatments. Now, as fi rst-generation drugs face patent expiry, the industry is pursuing technological and commercial opportunities that it hopes will yield the next generation of protein-based drugs, improving patient care and expanding market share.
Get the Answers You Need to Shape Your Strategy
Companies are developing technologies that will remodel recombinant protein and MAb therapeutics into next-generation drugs. What opportunities are being pursued for improving protein therapeutics? How will next-generation drugs improve upon their predecessors? Targeting protein therapeutics to reduce adverse side effects is an important goal and includes the creation of new classes of fusion proteins. Which companies are developing leading-edge technologies? What other advantages do targeted therapeutics hold? Researchers have developed promising new techniques for conjugating MAbs to various payloads, such as adding cytotoxic agents or radioisotopes to protein-based drugs. What are the advantages of these new protein conjugation techniques? Which companies lead the field? Demand for protein therapeutics grows each year, but manufacturing therapeutic proteins remains expensive and time-consuming. How are companies reducing cost and the time needed to produce recombinant proteins? Which methods are most promising?
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Current Landscape of Recombinant Protein and MAb Therapeutics
- The Protein Therapeutic Market
- Key Players in the Protein Therapeutic Marketplace
- First-Generation Protein Therapeutics
- Sidebar: Monoclonal Antibodies: An Important Class of Protein Therapeutics
- The Changing Landscape: Opportunities for Second-Generation Protein Therapeutics
- New Approaches in Developing Next-Generation Protein Therapeutics
- Increasing Affinity
- Targeting Therapeutics with Fusion Proteins
- Improving Potency Through Cytotoxicity
- Engineering Constant Regions
- Conjugated Protein Therapeutics .
- Reducing Immunogenicity
- Protein Production
- Corporate Profiles
- Affibody
- Ambrx
- Chromos Molecular Systems
- EvoGenix
- Seattle Genetics
- Trellis Bioscience
- Outlook for Protein Therapeutics
Tables
- 1. Marketed MAb Therapeutics
- 2. Recent Acquisitions in Proteins and MAbs
- 3. Select Companies in Protein/MAb Engineering/Production
Figures
- 1. Protein Therapeutic Market, 2005 and 2010
- A. Structural Components of an IgG Antibody
- B. Antibodies: From Mouse to Human
